HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
Author:
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
http://academic.oup.com/jnci/article-pdf/100/1/14/18074299/djm252.pdf
Reference24 articles.
1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group (EBCTCG);Lancet.,2005
2. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen non responsive tumours: results from the National Surgical Adjuvant Breast and Bowel Project B-15;Fisher;J Clin Oncol.,1990
3. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23;Fisher;J Clin Oncol.,2001
4. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer;Piccart;J Clin Oncol,2001
5. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma;Bang;Cancer.,2000
Cited by 315 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy;Clinical Breast Cancer;2024-08
2. Exploring the Potential of Nanomolecular Therapeutic Therapy Options, and Novel Biomarkers in Triple-negative Breast Cancer Treatment;Current Cancer Therapy Reviews;2024-06-11
3. A holistic review of recent advances in nano-based drug delivery systems for the treatment of triple-negative breast cancer (TNBC);Journal of Nanoparticle Research;2024-05
4. New insights into HER2-low breast cancer brain metastasis: A retrospective analysis;The Breast;2024-02
5. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer;Technology in Cancer Research & Treatment;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3